Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2015

Robbins Paul F, Kassim Sadik H, Tran Thai L N, Crystal Jessica S, Morgan Richard A, Feldman Steven A, Yang James C, Dudley Mark E, Wunderlich John R, Sherry Richard M, Kammula Udai S, Hughes Marybeth S, Restifo Nicholas P, Raffeld Mark, Lee Chyi-Chia R, Li Yong F, El-Gamil Mona, Rosenberg Steven A

Abstract excerpt

PURPOSE: Although adoptive cell therapy can be highly effective for the treatment of patients with melanoma, the application of this approach to the treatment of other solid tumors has been limited. The observation that the cancer germline (CG) antigen NY-ESO-1 is expressed in 70% to 80% and in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Epitopes, T-Lymphocyte

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-A2 Antigen

Share to Immunotherapy, Adoptive

Share to Pilot Projects

Share to Receptors, Antigen, T-Cell

Share to T-Lymphocyte Subsets

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 25538264
DOI: 10.1158/1078-0432.CCR-14-2708
PMCID: PMC4361810

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25538264-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.PMID 25538264Read ↗

Exploiting the curative potential of adoptive T‐cell therapy for cancerSemantic proximity Read ↗

Effective NY-ESO-1–specific MHC II–restricted T cell receptors from antigen-negative hosts enhance tumor regressionSemantic proximity Read ↗

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcomaSemantic proximity Read ↗

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancerSemantic proximity Read ↗

A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cellsSemantic proximity Read ↗

Human cancer-targeted immunity via transgenic hematopoietic stem cell progenySemantic proximity Read ↗

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.Semantic proximity Read ↗

Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell LinesSemantic proximity Read ↗

Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1Semantic proximity Read ↗

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigenSemantic proximity Read ↗

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.Semantic proximity Read ↗

Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.